The Latest Gene Therapy Industry Statistics Explained
The global gene therapy market was valued at $3.8 billion in 2019.
The statistic “The global gene therapy market was valued at $3.8 billion in 2019” indicates the total worth of the gene therapy industry worldwide in that particular year. This figure represents the sum of all revenues generated from the sale of gene therapy products and services across various regions and sectors. The value of the gene therapy market serves as a key indicator of the industry’s size, growth, and potential impact on healthcare and biotechnology sectors. It signifies the increasing interest and investment in gene therapy research, development, and commercialization due to its potential to revolutionize the treatment of genetic disorders and other diseases at the molecular level.
The market is predicted to grow at a compound annual growth rate (CAGR) of 19.3% from 2021 to 2028.
The statement indicates that the market is expected to experience significant growth over the specified period, with an average annual growth rate of 19.3%. This compound annual growth rate (CAGR) provides a clearer picture of the market expansion than a simple average would, as it accounts for the compounding effect of growth year over year. Therefore, if the market grows at a CAGR of 19.3%, it is projected to almost quintuple in size by the end of 2028 compared to its 2021 size. This prediction suggests a highly promising outlook for the market, indicating robust opportunities for businesses and investors operating within it.
Over 800 gene therapies are currently being developed worldwide.
The statistic that over 800 gene therapies are currently being developed worldwide indicates a significant and growing interest in the field of gene therapy research and development. Gene therapy involves the introduction, modification, or regulation of genes to treat or prevent diseases, making it a promising approach for addressing various genetic disorders and other health conditions. The large number of therapies in development suggests a diverse range of targets and applications for gene therapy across different medical specialties. This statistic highlights the increasing investment and focus on advancing gene therapy as a potential game-changer in the treatment of various diseases, paving the way for innovative and personalized treatment approaches in healthcare.
North America held the largest market share for gene therapy in 2020.
The statistic ‘North America held the largest market share for gene therapy in 2020’ indicates that the North American region, which includes countries like the United States and Canada, accounted for a higher percentage of the global gene therapy market compared to other regions. This suggests that North America was a prominent player in the development, adoption, and commercialization of gene therapy treatments in 2020. Factors contributing to this could include technological advancements, supportive regulatory environment, robust healthcare infrastructure, significant investments in research and development, and a higher prevalence of genetic disorders requiring gene therapy interventions. This statistic highlights the importance of North America in driving innovation and growth within the field of gene therapy during the specified timeframe.
As of 2019, there were over 2,600 studies underway related to gene therapy.
This statistic indicates a significant level of activity and interest in gene therapy research as of the year 2019. With over 2,600 studies underway, it suggests a robust effort by researchers and institutions to explore the potential of gene therapy as a promising treatment approach for various genetic disorders and diseases. The large number of studies reflects the growing importance and potential of gene therapy in the field of biotechnology and medicine, highlighting the ongoing advancements and significant investment in this area of research. This statistic underscores the increasing momentum and focus on gene therapy as a potentially transformative technology in the realm of healthcare and highlights the active involvement of the scientific community in advancing this field.
The viral vectors segment held the largest market share of the global gene therapy market in 2020.
The statement means that among all the different types of gene therapy technologies available in the global market in 2020, viral vectors were the most dominant and widely adopted approach. Viral vectors are delivery systems used to introduce therapeutic genes into target cells in gene therapy treatments. The fact that this segment held the largest market share indicates that viral vectors were the preferred choice among researchers, clinicians, and pharmaceutical companies for developing and delivering gene therapy products. This dominance may be attributed to the efficiency, specificity, and effectiveness of viral vectors in delivering genes to target cells for treating a wide range of genetic and acquired diseases.
The market size for the non-viral vectors segment in gene therapy is expected to reach $2.3 billion by 2027.
This statistic indicates the projected market size for the non-viral vectors segment within the gene therapy industry, with an expected value of $2.3 billion by the year 2027. Non-viral vectors are one of the key components in gene therapy, used to deliver therapeutic genes into target cells without the use of viruses. The increasing interest and investment in gene therapy, along with technological advancements in non-viral vector delivery systems, are likely driving the growth of this market segment. The forecasted market size suggests a significant opportunity for companies operating in this space, as well as potential benefits for patients seeking innovative treatments for genetic disorders and other diseases.
Oncology-based gene therapies accounted for the biggest market share in 2020.
This statistic indicates that in 2020, the largest proportion of the gene therapy market was dominated by treatments focused on oncology, which is the branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Oncology-based gene therapies refer to genetic interventions designed to target and combat various forms of cancer by modifying the genes in affected cells. The fact that this segment accounted for the biggest market share suggests that there is a strong demand and investment in developing gene therapies specifically for cancer treatment, reflecting both the prevalence of cancer as a major health concern and the promising potential of gene therapy in revolutionizing cancer care.
The CAGR for the oncology segment of the gene therapy market is expected to be 33.5% through 2028.
The Compound Annual Growth Rate (CAGR) of 33.5% for the oncology segment of the gene therapy market through 2028 indicates the expected average annual growth rate of the market specifically related to oncology treatments. This statistic suggests a rapid and significant expansion in the demand and adoption of gene therapy within the oncology field over the specified period. A CAGR of 33.5% implies a compounding growth rate, highlighting the potential for substantial market development and investment opportunities within this sector. This projection underscores the increasing importance and potential impact of gene therapy interventions in revolutionizing treatment options for cancer patients in the coming years.
As of 2022, the FDA has approved four gene therapy products.
As of 2022, the statistic that the FDA has approved four gene therapy products highlights the growing importance and advancements in gene therapy within the field of medicine. Gene therapy involves the alteration or modification of genetic material to treat various diseases and conditions. The fact that four gene therapy products have been approved by the FDA signifies a significant milestone in the development and acceptance of these novel treatment approaches. This statistic underscores the potential of gene therapy to revolutionize medical treatments and pave the way for more personalized and targeted therapies in the future.
The global gene therapy manufacturing market is expected to reach $14.6 billion by 2026.
The statistic indicates that the global gene therapy manufacturing market is forecasted to grow significantly and reach a market value of $14.6 billion by the year 2026. This growth reflects an increasing interest and investment in gene therapy technologies and treatments worldwide, as they hold promise for addressing a variety of genetic disorders and diseases. Factors such as advancements in genomic research, increased funding from both public and private sectors, and regulatory support for gene therapy development are likely driving this market expansion. The projected market value signifies substantial opportunities for biotechnology and pharmaceutical companies active in the gene therapy sector, as well as potential benefits for patients in need of innovative genetic treatments.
Europe is anticipated to witness significant gene therapy industry growth due to increasing government initiatives.
The statement suggests that the gene therapy industry in Europe is expected to experience notable growth in the foreseeable future, primarily driven by the rising number of government initiatives being implemented in the region. These initiatives likely include funding support, policy frameworks, and regulatory measures aimed at fostering research, development, and commercialization of gene therapies. As a result, the regulatory environment in Europe may become more favorable and conducive to innovation in the field of gene therapy, attracting investment and facilitating the emergence of new therapies to address various diseases and medical conditions. Overall, the anticipated growth in the gene therapy industry in Europe reflects a positive outlook for the sector and potential benefits for patients, healthcare systems, and the broader economy.
The market share of hospitals in the global gene therapy industry is predicted to grow at a CAGR of 33.9% through 2027.
This statistic indicates that the proportion of market share held by hospitals within the global gene therapy industry is anticipated to increase at a compound annual growth rate (CAGR) of 33.9% until the year 2027. This forecast suggests that hospitals are expected to play an increasingly significant role in the gene therapy market, capturing a larger share of the overall industry. The rapid growth rate implies a strong momentum and potential for expansion of hospital involvement in gene therapy-related services and treatments over the coming years, reflecting the rising importance of hospitals as key players in the evolving landscape of gene therapy technologies and applications.
The overall success rate for gene therapies in clinical trials is 17.6%.
The statistic “The overall success rate for gene therapies in clinical trials is 17.6%” refers to the proportion of gene therapy approaches that have demonstrated efficacy and safety to advance to the next stage of development or gain regulatory approval. A success rate of 17.6% suggests that a relatively small percentage of gene therapy treatments tested in clinical trials have been deemed effective, with many failing to show desired outcomes or encountering safety concerns. This statistic underscores the complex nature of developing gene therapies, as they involve modifying genetic material to treat or prevent diseases, which can pose challenges in terms of efficacy, safety, and regulatory approval. Continued research and advancements in gene therapy technology are needed to improve success rates and realize the potential of this innovative medical approach.
Adeno Associated Virus (AAV) has been the most preferred vector for 70% of ongoing gene therapy trials.
The statistic stating that Adeno Associated Virus (AAV) has been the most preferred vector for 70% of ongoing gene therapy trials indicates that a significant majority of gene therapy research projects are utilizing AAV as the vehicle for delivering genetic material into target cells. AAV is favored for its relatively low immunogenicity, ability to infect a wide range of cell types, and proven safety profile in humans. This statistic suggests that researchers have confidence in the efficacy and safety of AAV as a vector for gene therapy, leading to its widespread adoption in ongoing clinical trials.
The estimated approval rate for gene therapies in late-stage development is around 36%.
This statistic indicates that approximately 36% of gene therapy treatments that are in the late stages of development are expected to receive approval for market release. This approval rate suggests that gene therapies face significant challenges in the development process, with a substantial number of candidates failing to meet the regulatory standards necessary for approval. Factors influencing the relatively low approval rate may include complexities in demonstrating safety and efficacy, as well as issues related to manufacturing consistency and scalability. Thus, developers of gene therapies need to carefully navigate these hurdles in order to increase the likelihood of successful regulatory approval for their treatments.
There are more than 60 genes targeted by approved gene therapies as of 2020.
This statistic indicates that as of 2020, there are over 60 specific genes that have been identified and targeted for treatment through approved gene therapy interventions. Gene therapy involves introducing genetic material into a patient’s cells to potentially correct or modify a genetic condition. Having over 60 genes targeted by approved gene therapies signifies the increasing advancements in the field of genetic medicine and the potential for targeted treatments for various genetic disorders. This statistic highlights the ongoing progress in identifying gene targets and developing effective gene therapy approaches to address a wide range of genetic diseases and conditions.
Over 70% of the gene therapy market is dominated by the top 10 companies.
This statistic indicates that a significant portion of the gene therapy market is controlled by a small number of top companies. More specifically, it suggests that over 70% of the market share in the gene therapy industry is held by just 10 companies. This level of dominance by a select few players highlights the concentration of power and influence within the gene therapy market, potentially raising concerns about competition, innovation, and access to gene therapy products and technologies. As such, it underscores the need for careful monitoring and regulation to ensure a fair and competitive landscape in the gene therapy sector.
The FDA is expecting to approve 10–20 cell and gene therapies each year through 2025.
This statistic indicates that the Food and Drug Administration (FDA) is anticipating the approval of a significant number of cell and gene therapies annually until 2025, with an expected range of 10 to 20 approvals per year. This suggests a growing momentum and interest in advancing innovative treatments utilizing cell and gene technologies. The FDA’s willingness to approve a substantial number of these therapies reflects a recognition of their potential to address unmet medical needs and provide new treatment options for various diseases. The forecasted approval rate signals the agency’s commitment to facilitating the development and delivery of cutting-edge therapies to benefit patients within the next few years.
References
0. – https://www.www.nature.com
1. – https://www.www.fda.gov
2. – https://www.www.alliedmarketresearch.com
3. – https://www.www.researchandmarkets.com
4. – https://www.www.ncbi.nlm.nih.gov
5. – https://www.www.grandviewresearch.com
6. – https://www.www.fortunebusinessinsights.com
7. – https://www.www.globenewswire.com
8. – https://www.www.genome.gov
